Skip to content

Study · Other design · 2022

7 results

LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.

Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, O'Farrell LS, Briere DA, Sloop KW, Thomas MK, Pirro V, Wainscott DB and 8 more

Show all authors

Willard FS, Abernathy M, Morford L, Du Y, Benson C, Gimeno RE, Haupt A, Milicevic Z

Cell metabolism18 Aug 2022Cited by 240 (Europe PMC)

PMID35985340 (opens in a new tab)DOI10.1016/j.cmet.2022.07.013 (opens in a new tab)PepBankPUB-35985340
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 3 results from people.

  1. 01HumanOther designSafety outcome

    In a phase 1 single ascending dose study, LY3437943 showed a safety and tolerability profile similar to other incretins.

    In plain wordsIn a phase 1 study of single doses, retatrutide had a safety profile similar to other drugs of its type.

    Peptide
    Retatrutide
    Outcome
    Not applicableSafety and tolerability after a single ascending dose
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    single ascending dose · single doseAs given in this study (human).

    Source sentences

    Summary
    In a phase 1 single ascending dose study, LY3437943 showed a safety and tolerability profile similar to other incretins.
  2. 02HumanOther designPharmacokinetics

    In a phase 1 single ascending dose study, the pharmacokinetic profile of LY3437943 supported once-weekly dosing.

    In plain wordsIn a phase 1 study, how retatrutide moves through the body supported dosing once a week.

    Peptide
    Retatrutide
    Outcome
    Not applicablePharmacokinetic profile and dosing interval
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    single ascending dose · single doseAs given in this study (human).

    Source sentences

    Summary
    Its pharmacokinetic profile supported once-weekly dosing
    1 context sentence
    Summary · context
    In a phase 1 single ascending dose study, LY3437943 showed a safety and tolerability profile similar to other incretins.
  3. 03HumanOther designEfficacy outcome

    In a phase 1 single ascending dose study, a reduction in body weight after one dose of LY3437943 persisted up to day 43.

    In plain wordsIn a phase 1 study, weight loss after one dose of retatrutide lasted up to day 43.

    Peptide
    Retatrutide
    Outcome
    DecreaseBody weight after a single dose
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    single dose · 43 daysAs given in this study (human).

    Measurements

    Weight reduction persisted until day
    43 day
    after single dose

    Source sentences

    Summary
    a reduction in body weight persisted up to day 43 after a single dose.
    1 context sentence
    Summary · context
    In a phase 1 single ascending dose study, LY3437943 showed a safety and tolerability profile similar to other incretins.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In obese mice, administration of LY3437943 decreased body weight.

    In plain wordsIn obese mice, retatrutide lowered body weight.

    Peptide
    Retatrutide
    Outcome
    DecreaseBody weight in obese mice
    Study

    mousen: not reported in source

    Obese mice
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In obese mice, administration of LY3437943 decreased body weight and improved glycemic control.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In obese mice, administration of LY3437943 improved glycemic control.

    In plain wordsIn obese mice, retatrutide improved blood sugar control.

    Peptide
    Retatrutide
    Outcome
    IncreaseGlycemic control in obese mice
    Study

    mousen: not reported in source

    Obese mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In obese mice, administration of LY3437943 decreased body weight and improved glycemic control.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In obese mice, body weight loss with LY3437943 was augmented by glucagon receptor-mediated increases in energy expenditure on top of GIP and GLP-1 receptor-driven reduction of calorie intake.

    In plain wordsIn obese mice, retatrutide caused weight loss by raising energy use and lowering calorie intake.

    Peptide
    Retatrutide
    Outcome
    MixedEnergy expenditure and calorie intake in weight loss
    Study

    mousen: not reported in source

    Obese mice
    Outcome group
    Receptor activity and mechanism · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Body weight loss was augmented by the addition of GCGR-mediated increases in energy expenditure to GIPR- and GLP-1R-driven calorie intake reduction.
    1 context sentence
    Summary · context
    In obese mice, administration of LY3437943 decreased body weight and improved glycemic control.
  7. 07LabIn vitro (cells)Activity measurement

    In vitro, LY3437943 showed balanced glucagon receptor and GLP-1 receptor activity, but more GIP receptor activity.

    In plain wordsIn lab tests, retatrutide acted about equally on the glucagon and GLP-1 receptors and more strongly on the GIP receptor.

    Peptide
    Retatrutide
    Outcome
    Not applicableGCGR, GLP-1R and GIPR activity
    Study

    n: not reported in source

    In vitro
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vitro, LY3437943 shows balanced GCGR and GLP-1R activity but more GIPR activity.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.